Delayed Hypersensitivity Reactions to Infliximab Infusion: Case Report
Christos Sotiropoulos1*, Eftichia Sakka2, Georgios Theocharis3 and Konstantinos Thomopoulos4 Inflammatory Bowel Disease is a chronic, relapsing disease that occurs with acute flare ups and remissions. Among the existing therapies, biological agents have revolutionized the management and the natural progress of the disease, but without lacking side effects. Infliximab, a chimeric monoclonal antibody that suppresses the



















